FDA clears IND for Prothena's PRX012 subcutaneous anti-Aβ antibody; Phase 1 SAD study initiated

PROTHENA CORP PUBLIC LTD CO

FDA cleared IND for PRX012, a potential best-in-class anti-amyloid beta antibody for Alzheimer's disease.
Phase 1 single ascending dose study in healthy volunteers and AD patients has started; MAD study expected by year-end 2022.
PRX012 designed for subcutaneous dosing with high binding potency; preclinical data show plaque occupancy at low doses.
Prothena expects PRX012 to serve as a foundational anti-Aβ treatment with convenient administration.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.